- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00706550
Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects
Immune Responses to Pneumococcal Vaccination Among HIV-Infected Subjects
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Michael E DeBakey VA Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- HIV infected
- CD4 count >200
- no acute illness
- no pneumococcal vaccination within 3 years
- naive to treatment or if previously on treatment, no antiretroviral treatment for at least 6 months
- willingness to start antiretroviral treatment as recommended by current guidelines
Exclusion Criteria:
- prior pneumococcal vaccination within 3 years
- prior AIDS diagnosis based on opportunistic disease
- acute illness
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Otro: Immediate
Arm 1 will receive PV (23-valent pneumococcal polysaccharide vaccine) prior to starting antiretroviral treatment and will receive PLACEBO after at least 6 months of starting antiretroviral treatment. PV (23-valent pneumococcal polysaccharide vaccine): Currently commercially available pneumococcal polysaccharide vaccine |
Placebo
Currently commercially available pneumococcal polysaccharide vaccine
Otros nombres:
|
Otro: Delayed
Arm 2 will receive PLACEBO prior to starting antiretroviral treatment and will receive PV (23-valent pneumococcal polysaccharide vaccine) after at least 6 months of starting antiretroviral treatment. PV (23-valent pneumococcal polysaccharide vaccine): Currently commercially available pneumococcal polysaccharide vaccine |
Placebo
Currently commercially available pneumococcal polysaccharide vaccine
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Immunoglobulin G (IgG) Levels
Periodo de tiempo: Baseline
|
Immunoglobulins are antibodies or special proteins that the immune system produces to protect the body against infections.
IgG is the most common antibody.
We measure baseline levels (before the vaccine is administered) to know how much antibody the subject has at the start point to be able to evaluate how much antibody is produced after the vaccine is administered.
|
Baseline
|
IgG Levels
Periodo de tiempo: One-month post-vaccine
|
Immunoglobulins are antibodies or special proteins that the immune system produces to protect the body against infections.
IgG is the most common antibody.
This point of time (one-month after vaccine), gives the information about how much antibody was produced by the participant's immune system in response to the vaccine.
|
One-month post-vaccine
|
Immunoglobulin M (IgM) Levels
Periodo de tiempo: Baseline
|
Immunoglobulins are antibodies or special proteins that the immune system produces to protect the body against infections.
IgM is the first antibody produced by the immune system to fight a new infection.
We measure baseline levels (before the vaccine is administered) to know how much antibody the subject has at the start point to be able to evaluate how much antibody is produced after the vaccine is administered.
|
Baseline
|
IgM Levels
Periodo de tiempo: One-month post-vaccine
|
Immunoglobulins are antibodies or special proteins that the immune system produces to protect the body against infections.
IgM is the first antibody produced by the immune system to fight a new infection.
This point of time (one-month after vaccine), gives the information about how much antibody was produced by the participant's immune system in response to the vaccine.
|
One-month post-vaccine
|
Opsonophagocytic Killing Activity (OPA)
Periodo de tiempo: Baseline
|
This assay helps us to know how the antibody produced by the body are working to kill the bacteria against which the antibody is produced.
As explained previously for the immunoglobulins' assays, we measure the baseline point to be able to determine the increase after the vaccine is administered.
|
Baseline
|
Opsonophagocytic Killing Activity (OPA)
Periodo de tiempo: One-month post-vaccine
|
This assay helps us to know how the antibody produced by the body are working to kill the bacteria against which the antibody is produced.
This point of time (one-month after vaccine), gives the information about how much the killing activity increased 1 month after the vaccine was administered.
|
One-month post-vaccine
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Maria Rodriguez-Barradas, MD, Michael E. DeBakey VA Medical Center
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones transmitidas por la sangre
- Enfermedades contagiosas
- Enfermedades De Transmisión Sexual Virales
- Enfermedades de transmisión sexual
- Infecciones por lentivirus
- Infecciones por retroviridae
- Síndromes de deficiencia inmunológica
- Enfermedades del sistema inmunológico
- Infecciones por VIH
- Efectos fisiológicos de las drogas
- Factores inmunológicos
- Vacuna antineumocócica conjugada heptavalente
Otros números de identificación del estudio
- INDA-002-08S
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Infecciones por VIH
-
Icahn School of Medicine at Mount SinaiIRRASReclutamientoHemorragia Intraventricular (HIV)Estados Unidos
-
Yale UniversityTerminadoPrecocidad | Recién nacidos de muy bajo peso al nacer | Hemorragia Intraventricular (HIV) | Sangrado en el cerebroEstados Unidos
-
China Medical University HospitalDesconocidoDisplasia broncopulmonar | Bebés extremadamente prematuros | TLP grave que las terapias convencionales han fallado | Sin anomalías congénitas graves | no Hiv Severa Ni FPV QuísticaTaiwán